CMS chief: ‘Individual market was working much better’ prior to ACA

CMS Administrator Seema Verma said the blame for rising premiums and fewer insurers in the Affordable Care Act (ACA) exchanges fall on the prior administration, not the current one, while offering a mixed message on the American Health Care Act (AHCA), the ACA replacement that passed the House earlier in May.

In an interview with USA Today, Verma said the exchanges are “falling apart.”

“Right now, if we look at it, this is all because of the Affordable Care Act," she said. “I mean, the individual market was working much better than it is now, so this is all the impact of the Affordable Care Act.”

Insurers are again requesting double-digit hikes in premiums for 2018, but have put the blame on uncertainty created by the Trump administration not guaranteeing support for cost-sharing reduction (CSR) subsidies that go to insurance companies. Blue Cross and Blue Shield of North Carolina spelled out the financial impact of that uncertainty, saying it’s requesting a 22.9 percent average increase in premiums for 2018 because of it. If the CSRs were funded, it said it would request only a 8.8 percent hike.

Verma also disputed the recent Congressional Budget Office (CBO) report on the Republican-sponsored AHCA. She called past CBO estimates on insurance coverage “problematic,” but also said the House bill isn’t as important because the legislation is very likely to be changed by the Senate.

“Really, the House version is something that's outdated at this point," Verma said.

Read the full article at the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.